drugset / Trial / NCT04165174
PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT
NaSingle-groupOpen-labelTreatment
Summary
It is a trial to assess the efficacy and safety of PD-1 monoclonal antibody plus Apatinib combined with SBRT as first-line treatment in HCC with PVTT.
Timeline
- Start
- 2019-12
- Primary completion
- 2020-11
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | Terepril | Monoclonal antibody | 240 mg | Intravenous |